Comprehensive medication guide to {drug} including estimated pricing, availability information, side effects, and how to find it in stock at your local pharmacy.
Fondaparinux is a synthetic selective Factor Xa inhibitor used as an anticoagulant (blood thinner) to prevent and treat blood clots. It's approved for preventing deep vein thrombosis (DVT) in patients undergoing hip, knee, or abdominal surgery, and for treating acute DVT and pulmonary embolism. Unlike heparin, Fondaparinux is given as a once-daily subcutaneous injection and does not require routine blood monitoring. The brand name is Arixtra, but generic versions are widely available.
Fondaparinux is a synthetic pentasaccharide that selectively binds to antithrombin III, enhancing its natural ability to inhibit Factor Xa by approximately 300-fold. By blocking Factor Xa, it interrupts the blood coagulation cascade and prevents thrombin formation and subsequent clot development. Unlike heparin, Fondaparinux does not directly inhibit thrombin (Factor IIa), making it more selective and potentially causing fewer bleeding complications than traditional heparins.
Fondaparinux has experienced intermittent supply disruptions, with certain strengths (particularly 2.5 mg and 7.5 mg) having limited availability from some manufacturers. The medication has a findability score of 55/100, indicating moderate availability challenges. Supply issues stem from the limited number of generic manufacturers and the complexity of producing this synthetic pentasaccharide anticoagulant. Check with multiple pharmacies or use Medfinder to locate available stock.
Struggling to find {drug} in stock? We'll call the pharmacies, sit on hold, and find you one that can fill your prescription.
Fondaparinux is typically prescribed by specialists including hematologists, orthopedic surgeons, general surgeons, cardiologists, and vascular medicine physicians. Internal medicine doctors, hospitalists, pulmonologists, and emergency medicine physicians may also prescribe it for blood clot prevention and treatment. The medication is usually started in a hospital or surgical setting, though patients can be trained to self-inject at home for extended therapy.
No, Fondaparinux is not a controlled substance and does not require a DEA number for prescribing. However, it is a prescription-only medication that requires careful monitoring for bleeding complications. Some insurance plans may classify it as a specialty medication, and prior authorization may be required for certain uses or extended treatment durations.
Fondaparinux is an effective anticoagulant for preventing and treating blood clots, particularly valuable for patients who cannot use heparin. While supply disruptions have created availability challenges, generic versions offer significant cost savings over the brand. The once-daily injection schedule and lack of required blood monitoring make it convenient for outpatient use. Work with your healthcare provider and pharmacist to ensure consistent access, and consider using Medfinder to locate available stock when supplies are tight.
%2C%20Color%3DOriginal.png)
